Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

Required: IDH1 wild-type

Required: IDH2 wild-type

Must have received: surgery — initial therapy

An initial therapy requires surgery and radiation therapy, with or without temozolomide. In addition, alternate therapy (with or instead of temozolomide) is permitted as part of initial therapy.

Must have received: radiation therapy — initial therapy

An initial therapy requires surgery and radiation therapy, with or without temozolomide. In addition, alternate therapy (with or instead of temozolomide) is permitted as part of initial therapy.

Cannot have received: immunotherapy

Prior treatment involving immunotherapy, including oncolytic viruses, therapeutic vaccination, or biologics (e.g. monoclonal antibodies, such as bevacizumab) presumed to have immunomodulatory effects.

Cannot have received: systemic therapy after first recurrence

Radiation therapy, local therapy (except for surgical re-resection), or systemic therapy following first recurrence/progressive disease.

Cannot have received: Optune (Optune)

Exception: Previous use of Optune in the primary setting does not preclude participation in this clinical trial.

Concurrent therapy with Optune® or use within 1 week of start of treatment. Previous use of Optune® in the primary setting does not preclude participation in this clinical trial.